8-K: Report of unscheduled material events or corporate event Post author:andrewkaretas Post published:August 1, 2025 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading8-K: Report of unscheduled material events or corporate event
SCHEDULE 13G: SCHEDULE 13G – Description Post author:andrewkaretas Post published:July 16, 2025 Post category:SEC Filings Allogene Therapeutics, Inc. Continue ReadingSCHEDULE 13G: SCHEDULE 13G – Description
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:June 23, 2025 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
ALLO-316 in Advanced Clear Cell Renal Cell Carcinoma: Updated Results From the Phase 1 TRAVERSE Study Post author:andrewkaretas Post published:June 1, 2025 Post category:CD70/Scientific Publications Continue ReadingALLO-316 in Advanced Clear Cell Renal Cell Carcinoma: Updated Results From the Phase 1 TRAVERSE Study
ALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts) With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy Post author:andrewkaretas Post published:June 1, 2025 Post category:CD19/Scientific Publications Continue ReadingALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts) With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy
“Off-the-shelf” CAR T—New frontiers in autoimmune disease Post author:andrewkaretas Post published:May 7, 2025 Post category:Perspectives Continue Reading“Off-the-shelf” CAR T—New frontiers in autoimmune disease
Allogeneic Chimeric Antigen Receptor T‑Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B‑Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies Post author:andrewkaretas Post published:February 12, 2025 Post category:CD19/Scientific Publications Continue ReadingAllogeneic Chimeric Antigen Receptor T‑Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B‑Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies
Supplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies Post author:andrewkaretas Post published:February 12, 2025 Post category:CD19/Scientific Publications Continue ReadingSupplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies
Alpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy Post author:andrewkaretas Post published:December 9, 2024 Post category:CD19/Scientific Publications Continue ReadingAlpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy
Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases Post author:andrewkaretas Post published:November 18, 2024 Post category:Dual/Scientific Publications Continue ReadingPreclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases
